Abstract: A drinkable infant composition comprising two or more food allergens wherein one of said food allergens is milk protein.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of non-replicating L. johnsonii La1 NCC533 (deposit number CNCM I-1225) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: The subject or the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Abstract: The invention relates to newly identified peptides of that are capable of inducing tolerance to cow's milk, especially to ?-lactoglobulin. The peptides may be administered to mammals, especially to young infants who are at risk of allergy to cow's milk proteins, to induce oral tolerance to cow's milk; they may also be administered to children or adults who are allergic to cow's milk to allow “desensitization” towards the allergenic milk proteins, especially ?-lactoglobulin, to occur. The peptides may also be used to induce tolerance to goat's and buffalo's milk proteins, especially ?-lactoglobulin. The peptides are capable of modulating the mammalian immune response to allergens.

Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Abstract: The invention relates to newly identified peptides of that are capable of inducing tolerance to cow's milk, especially to ?-lactoglobulin. The peptides may be administered to mammals, especially to young infants who are at risk of allergy to cow's milk proteins, to induce oral tolerance to cow's milk; they may also be administered to children or adults who are allergic to cow's milk to allow “desensitization” towards the allergenic milk proteins, especially ?-lactoglobulin, to occur. The peptides may also be used to induce tolerance to goat's and buffalo's milk proteins, especially ?-lactoglobulin. The peptides are capable of modulating the mammalian immune response to allergens.

Abstract: Bifidobacterium breve CNCM I-3865 (NCC2950), a composition comprising Bifidobacterium breve CNCM I-3865 (NCC2950), and the use of Bifidobacterium breve CNCM I-3865 (NCC2950) in the prevention or treatment of allergic diarrhoea are provided. The Bifidobacterium breve CNCM I-3865 (NCC2950) can be in a non-replicating form and can be administered to at least partially treat allergic diarrhoea or at least partially reduce the risk of developing allergic diarrhoea.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention can help parents to protect their children from such upper respiratory tract infections.

Abstract: The present invention relates to the field of infant nutrition. In particular, the present invention relates to infant feeding formulas comprising probiotic micro-organisms. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.

Abstract: The present invention relates to non-replicating probiotic micro-organisms and their health benefits. In particular, the present invention provides a means to help parents to protect their children from gastro-intestinal infections, in particular diarrhea. One embodiment of the present invention relates to a composition comprising non-replicating probiotic micro-organisms for use in the prevention or treatment of gastrointestinal infections in children.

Abstract: The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms.

Abstract: The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Abstract: The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms.

Abstract: The present invention relates to the field of frozen yoghurt. In particular, the present invention provides frozen yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may bioactive heat treated probiotic micro-organisms, for example. The present inventions also relates to health benefits provided by these non-replicating probiotic micro-organisms.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM 1-2618) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defenses. One embodiment of the present invention is the use of B. longum NCC2705 (deposit number CNCM 1-2618) for use in the treatment or prevention of disorders related to the immune system including infections.

Abstract: The present invention relates to the fields of hydration and nutrition for dysphagic patients. In particular, the present invention relates to thickeners comprising probiotic microorganisms and to compositions comprising such thickeners. The probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic microorganisms.

Abstract: The present invention provides a probiotic, Lactobacillus paracasei NCC 2461, i.e. ST11, for use by administration to expectant females and/or lactating mothers, and to their progeny for the reduction or prevention of the development of allergic immune responses in progeny. A daily dose of ST11 is administered to a pregnant woman for at least two weeks before delivery and, after delivery, the daily dose of ST11, is administered to the lactating mother or the newborn infant for at least two months, either directly or via the mother's milk. The infant immune responses to allergens are thus reduced, resulting in a “dampened” allergic response. Thus allergy, including atopy, may be prevented in the progeny.

Abstract: The present invention relates to the field of nutrition for children. In particular, the present invention relates to the nutritional compositions intended for children with an impaired function of the gastro-intestinal tract. One embodiment of the present invention relates to a nutritional composition to be administered to children with an impaired function of the gastrointestinal tract comprising probiotic micro-organisms. The probiotic micro-organisms may be non-replicating, for example bioactive heat treated probiotic micro-organisms.